Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;45(9):567-568.
doi: 10.1016/j.medine.2021.10.007. Epub 2021 Oct 25.

SEDAR-SEMICYUC consensus on the management of haemostasis disorders in severe COVID-19 patients

J V Llau  1 , R Ferrandis  2 , P Sierra  3 , F Hidalgo  4 , C Cassinello  5 , A Gómez-Luque  6 , M Quintana  7 , R Amezaga  8 , M Geroi  9 , A Serrano  10 , P Marcos  11
Affiliations

SEDAR-SEMICYUC consensus on the management of haemostasis disorders in severe COVID-19 patients

J V Llau et al. Med Intensiva (Engl Ed). 2021 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of the recommendations for the management of anticoagulants and antiplatelet drugs in severe COVID-19 patients. ASA: acetylsalicylic acid; DOAC: direct oral anticoagulant; AVK: anti-vitamin K; DD: D dimer; VTED: venous thromboembolic disease; AF: atrial fibrillation; GFR: glomerular filtration rate; FIB: fibrinogen; LMWH: low molecular weight heparin; UFH: unfractionated heparin; NR: normal range; HIT: heparin-induced thrombocytopenia; IMV: invasive mechanical ventilation; NIMV: noninvasive mechanical ventilation.
See this image and copyright information in PMC

References

    1. Llau J.V., Ferrandis R., Sierra P., Hidalgo F., Cassinello C., Gómez-Luque A., et al. Recomendaciones de consenso SEDAR-SEMICYUC sobre el manejo de las alteraciones de la hemostasia en los pacientes graves con infección por COVID-19. Rev Esp Anestesiol Reanim. 2020;67:391–399. - PMC - PubMed